7/2/2023 0 Comments Coronavirus new findings![]() ![]() Data were stratified by age, and a benefit was seen only for people 65 years and older. About 80% of participants were considered fully vaccinated. The analysis was adjusted for comorbidities, demographics, ethnicity/religious affiliation, and socioeconomic status. They compared patients who did and did not receive Paxlovid within five days of a confirmed diagnosis of COVID-19. This study from a large health system in Israel identified adults 40 years and older eligible to receive the drug during the Omicron surge. The primary study used to approve nirmatrelvir/ritonavir (Paxlovid) for use in outpatients with COVID-19 included only high-risk, unvaccinated patients. Nirmatrelvir/Ritonavir (Paxlovid) Reduces Hospitalization and Mortality in Older, High-Risk Patients with COVID-19, but Data in Younger Vaccinated Patients Is Inconsistent. Recurrence of symptoms following a 2-day symptom free period in patients with COVID-19. (Source: Smith DM, Li JZ, Moser C, et al. The bottom line is that symptomatic recurrences are common with or without Paxlovid and are generally mild. An interesting and informative diagram provided with the research lets you examine these recurrences for individual participants yourself. The interval between resolution of the initial symptoms and recurrence varied from one day to more than two weeks later, so some of these recurrences may represent a separate viral illness about half recurred in the first week following resolution. The recurrent symptoms were largely mild, with no patient reporting severe recurrent symptoms and only eight of the 48 reporting moderate severity symptoms for at least one day. The most common recurrent symptoms were cough (44%), fatigue (35%), and headache (35%). Of these 108, 48 (44%) reported at least one symptom recurring for at least one day during the follow-up period. ![]() During the 28 days of follow-up, 108 of 158 participants (68%) achieved complete resolution of all symptoms for at least two consecutive days. The participants had a median age of 47 years, 50% were women, 18% self-identified as part of a minority racial group, and 31% identified as Hispanic. The 158 participants in the placebo group completed a daily symptom diary for 28 days, tracking 13 symptoms. But is this causally related to use of the drug, or is it just part of the natural history of infection with SARS-CoV-2? These authors used data from the placebo group in the ACTIV-2 randomized trial that compared Paxlovid with placebo in outpatients symptomatic with COVID-19 for 10 or fewer days. Rebound Symptoms Common With COVID-19 Even After Placebo Treatment.“Paxlovid rebound” has been widely reported by patients and in the media and is defined as someone who has recurrent symptoms who had initially recovered following a five-day course of Paxlovid (nirmatrelvir/ritonavir). ![]()
0 Comments
Leave a Reply. |